Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer

KRAS mutations are an established predictor of lack of response to EGFR-targeted therapies in patients with metastatic colorectal cancer (mCRC). However, little is known about the role of the rarer NRAS mutations as a mechanism of primary resistance to the anti-EGFR monoclonal antibody cetuximab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Queralt, Bernardo, Cuyàs, Elisabet, Bosch-Barrera, Joaquim, Massaguer, Anna, de Llorens, Rafael, Martin-Castillo, Begoña, Brunet, Joan, Salazar, Ramon, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347684/
https://www.ncbi.nlm.nih.gov/pubmed/27636997
http://dx.doi.org/10.18632/oncotarget.11985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347684/
https://www.ncbi.nlm.nih.gov/pubmed/27636997
http://dx.doi.org/10.18632/oncotarget.11985

Ejemplares similares